Lv4
420 积分 2023-05-08 加入
Effect of one or two cycles of dual immunotherapy with nivolumab and ipilimumab in patients with mismatch repair-deficient rectal cancer (RESET-R): interim results from a multicentre, single-arm, phase 2 trial
18天前
已完结
HER2 and urothelial carcinoma: current understanding and future directions
19天前
已完结
Preclinical characterization and phase 1 results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors
20天前
已关闭
DART (NCI/SWOG S1609): Comprehensive Final Results from Dual Checkpoint Inhibition with CTLA-4 and PD-1 Blockade in Rare Cancers
20天前
已关闭
Is there a future for Trop-2-targeted ADCs in urothelial carcinoma?
20天前
已完结
Optimizing local control in the surgical management of bladder cancer
4个月前
已完结
[Immune checkpoint inhibitors-related hyperprogressive disease: a case report]
4个月前
已完结
Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
4个月前
已完结
First and Second-line Treatments in Metastatic Renal Cell Carcinoma
5个月前
已完结
Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis
5个月前
已完结
皖公网安备34019202002308
